Liminatus Pharma Inc. Class A Common Stock

LIMN | NASDAQ

Price Alert Chart Builder DCF Calculator

$4.07

+$0.43 (+11.81%)

At close: Sep 22, 2026, 4:00 PM ET

$4.09

+$0.02 (+0.49%)

After-hours: Sep 22, 2026, 7:50 PM ET

Overview Rating Statistics Financials Earnings Analysts Ownership Profile

+11.81%

(1D)

Rating

Updated: Aug 22, 2026

17.5

Fundamentals Weak

Market Sentiment Neutral

Moat Narrow

Full Analysis

Key Statistics

Market Data

Market Cap $5.47M

1D Range

3.64 4.26

52W Range

3.29 141.50

Valuation (TTM)

PE -0.16

PB 16.26

EV/EBITDA -0.27

Valuation (NTM)

Forward PE N/A

Forward PEG -0.00

Price Target N/A

Cash Flow

FCF Yield -81.5%

SBC Adj. FCF Yield -81.5%

SBC Impact N/A

Margins

Gross Margin 0.0%

Operating Margin 0.0%

FCF Margin N/A

Growth (CAGR)

Revenue 3Y | 5Y N/A | N/A

Dil EPS 3Y | 5Y -42.9% | N/A

FCF 3Y | 5Y -60.5% | N/A

Returns

ROA -367.9%

ROE 443.6%

ROIC -225.1%

Financial Health

Net Cash

$1.57M

Current Ratio 1.12

Interest Coverage -53.78

Dividends

Div Yield N/A

Payout Ratio N/A

FCF Payout Ratio N/A

All Key Statistics

Loading financial charts...

Profile

Liminatus Pharma, Inc. is an immuno-oncology firm, currently in its clinical development phase, dedicated to pioneering new treatments for cancer. The company's headquarters are located in La Palma, C...

Sector Healthcare

Industry Biotechnology

Employees 1

IPO Date Apr 30, 2025

Website liminatuspharma.com

Fiscal Year January - December

Full Company Profile

Latest News

No news articles available yet.